Literature DB >> 1086656

Effect of penicillamine treatment on immune complexes in two cases of seropositive juvenile rheumatoid arthritis.

F P Bresnihan, B M Ansell.   

Abstract

A correlation has previously been observed between the presence of enhancing complexes and cutaneous vasculitis in rheumatoid arthritis. Two parients with seropositive juvenile rheumatoid arthritis are described in whom enhancing complexes were detected before the appearance of cutaneous vasculitis. Their contrasting response to penicillamine is discussed in relation to the role of of rheumatoid factor and antinuclear antibodies.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1086656      PMCID： PMC1006582          DOI： 10.1136/ard.35.5.463

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  4 in total

1.  Detection and radioassay of soluble circulating immune complexes using guinea pig peritoneal exudate cells.

Authors:  I I Onyewotu; E J Holborow; G D Johnson
Journal:  Nature       Date:  1974-03-08       Impact factor: 49.962

2.  The treatment of rheumatoid arthritis and necrotizing vasculitis with penicillamine.

Authors:  I A Jaffe
Journal:  Arthritis Rheum       Date:  1970 Jul-Aug

3.  Trial comparing D-penicillamine and gold in rheumatoid arthritis. Preliminary report.

Authors:  E C Huskisson; T J Gibson; H W Balme; H Berry; H C Burry; R Grahame; F D Hart; D R Henderson; J A Wojtulewski
Journal:  Ann Rheum Dis       Date:  1974-11       Impact factor: 19.103

4.  Enhanced uptake by guinea-pig macrophages of radio-iodinated human aggregated immunoglobulin G in the presence of sera from rheumatoid patients with cutaneous vasculitis.

Authors:  I I Onyewotu; P M Johnson; G D Johnson; E J Holborow
Journal:  Clin Exp Immunol       Date:  1975-02       Impact factor: 4.330
  4 in total
  2 in total

1.  Immune complexes in juvenile chronic arthritis.

Authors:  U Latzka; E J Menzel; W Granninger; C Steffen
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

Review 2.  A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis.

Authors:  A A Kalla; A F Tooke; E Bhettay; O L Meyers
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.